Viewing nowPregatin Capsule 25 Milligrams (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
Hana Pharmaceutical Co., Ltd.

MFDS item code 201900613 · Approved 2019.01.23 · Insurance code 657806390
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
This medication is used to treat peripheral and central neuropathic pain in adults. It is also used as an adjunct in the treatment of partial seizures in patients with epilepsy, and helps alleviate symptoms of fibromyalgia. Therefore, it is an effective drug for the treatment of neuropathic pain, epileptic seizures, and fibromyalgia.
This medicine is administered orally, regardless of food, in two divided doses of the total daily dose of pregabalin. Since this medicine is mainly excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is excreted mainly by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the administration regimen. b: The supplemental dose refers to an additional dose administered once. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because sufficient safety and efficacy data are not available. Adolescents aged 12-17 years: Administration is not recommended because sufficient safety and efficacy data are not available.
This medication may increase the risk of suicidal thoughts or behavior, so immediately consult a physician if mood changes or abnormal behavior occur during treatment. Patients with an allergy to the components of this medication or those with certain genetic metabolic issues should not take it. Diabetic patients may be affected in blood sugar control due to weight gain, so dosage adjustments should be made according to a physician's directions. If severe allergic reactions such as angioedema occur, stop taking the medication immediately and inform healthcare personnel. Elderly patients should be especially cautious during the initial phase of treatment due to the increased risk of falls from dizziness and drowsiness. Report to a physician if there are visual disturbances or other changes in vision that do not improve. Abrupt discontinuation of this medication can lead to withdrawal symptoms such as insomnia, headaches, and anxiety, so dosage should be gradually reduced according to a physician's directions. Due to the risk of drug abuse, patients with a history of substance abuse should consult healthcare personnel before taking it. Patients with reduced kidney function need to adjust their dosage, and patients with heart disease should also take it with caution. Taking this medication with opioid analgesics can increase central nervous system depressant effects, so caution is necessary when used together. This medication can cause dizziness and drowsiness, so symptoms should be confirmed before driving or operating hazardous machinery. During early pregnancy, it may affect the fetus, so women who are pregnant or planning to conceive must consult with healthcare personnel before use. This medication may be passed into breast milk, so nursing mothers should discuss breastfeeding and medication use with their doctor. In cases of overdose, symptoms such as confusion, drowsiness, and depression may occur, and immediate emergency treatment should be sought. Keep this medication out of the reach of children, and do not transfer it to other containers for safety reasons.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, and it is advisable to keep it in a cool place between 15 to 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer period.
A hard capsule of upper beige and lower white containing a white powder that is white or light yellow in color.
Domestic - 30 capsules/bottle, Domestic - 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
Hana Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.